Hydroxylansoprazole methods

Details Hydroxylansoprazole methods Hydroxylansoprazole methods

2006-08-29

2006-08-29

Jones, Dwayne C. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07098224

ABSTRACT:
Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

REFERENCES:
patent: 4628098 (1986-12-01), Nohara et al.
patent: 4689333 (1987-08-01), Nohara et al.
HCAPLUS DN 123:132521, Fort F et al.
HCAPLUS DN 115:21996, Inatomi N et al, Yakuri to Chiryo, 1991, 19(2) 477-86, abstract.
JICST-Eplus AN 961013832, Nakamura K et al, J clin Ther Med, 1996 12 (13) 2775-2788, abstract.
Katsuki et al. “Determination of R(+)-and S(−)-Lansoprazole Using Chiral Stationary-Phase Liquid Chromatography . . . ”Pharm. Res. 13, 611-615 (1996).
Pearce et al. “Identification of the Human P450 Enzymes Involved in Lansoprazole Metabolism”J. Pharm. Exp. Ther. 277, 805-816 (1996).
Fort et al. “Mechanism for Species-Specific Induction of Leydig Cell Tumors in Rats by Lansoprazole”Fund. Appl. Toxicol. 26, 191-202 (1995).
Andersson “Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors”Clin. Pharmacokinet 1, 9-28 (1996).
Chem. Abstract 115:21996.
Katsuki et al. “Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects”Eur. J. Clin. Pharmacol. 52, 391-396 (1997).
Nagata et al. “Growth Inhibition ofUreaplasma Urealyticumby the Proton Pump Inhibitor Lansoprazole: Direct Attribution to Inhibition . . . ”Anti, Agents Chemo. 39, 2187-2192 (1995).
Sohn et al. “Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hdroxylation phenotype status”Clin. Pharm. Ther, 61, 574-582 (1997).
Pichard et al. “Oxidative Metabolism of Lansoprazole by Human Liver Cytochromes P450”Mol. Pharm. 47, 410-418 (1995).
Aoki et al. “High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine”J. Chromatography 571, 283-290 (1991).

Affiliated with

Also associated with

Rating

Hydroxylansoprazole methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxylansoprazole methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxylansoprazole methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3705119